Redox Signaling

Erscheinungsjahr 2024
ISBN: 978-0-443-29444-0
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 430 g

Advances in Cancer Research, Volume 162 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of authors.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Townsend, Danyelle

Schmidt, Ed

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Mikrobiologie
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Cellular cysteine sources and availability in cancer
Ed Schmidt
2. PTP1B
Lalima Katyayani K. Madan
3. Mitochondrial metallopeptidase OMA1 in cancer
Oleh Khalimonchuk
4. Redox Regulation of VDAK
Eduardo Nestor Maldonado
5. Role of thiols or antioxidants in modulating immune response
Shikhar Mehrotra
6. Redox regulation in melanoma metastasis and targeted therapy resistance
Danyelle Townsend and Jie Zhang
7. chapter to be determined
Kenneth D. Tew
8. title yet to be determined
Hozumi Motohashi
9. title yet to be determined
Mark Hampton
10. title yet to be determined
Colin Miller
11. GRP78 as novel molecular targets through ER stress modulation in lung cancer
Zhi-wei Ye

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.